Active surveillance of sporadic renal masses: experience from a single tertiary centre
BAUS ePoster online library. Neves J. 06/27/18; 211378; P9-6 Disclosure(s)(s): None
Joana B Neves
Joana B Neves
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Objective: We report on the natural history of renal lesions under active surveillance at a tertiary high-volume referral centre in the UK.
Methods: Retrospective analysis of cases with suspected renal cell carcinoma (RCC) at diagnosis under active surveillance from 2012 to 2017. Patients with confirmed hereditary syndromes were excluded.

Results: 286 patients (62.9% male, median age at diagnosis 71 - IQR 18) with 350 lesions were reviewed. Median lesion size was 24.5mm (IQR 20): 291(83.1%) under 4cm (small renal mass, SRM) and 17(4.6%) above 7cm. 56 lesions were excluded due to lack of follow-up imaging at date of analysis. Median follow-up was 12 months (IQR 20). Histology was known for 135 lesions (45.9%): 73 were RCC, 40 oncocytomas, 9 oncocytic, 10 angiomyolipomas, 2 papillary adenomas, and 1 angiofibroma. During follow-up 156(53.1%) lesions remained stable, 21(7.1%) reduced size and 117(39.8%) increased in size. Increasing lesions grew a median of 4mm/year( IQR 6.6). Focusing on SRM, the median growth was 2.6mm/year(IQR 4.2), and 16(6.6%) went over the 4cm threshold. 31(10.8%) patients changed management after a period of surveillance (17 surgery, 14 percutaneous cryoablation). One patient developed metastasis (cT1b clear cell RCC on a patient unfit for intervention). No cancer specific deaths occurred, but there were 10 non-cancer specific deaths. Study limitations include retrospective nature, lack of central radiological review, and short follow up period.

Conclusions: While our SRM median yearly growth rate is comparable to previous reports, a higher proportion of cases breached the 4cm threshold. Notwithstanding, metastasis-free and cancer-specific survival were close to 100%.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings